Navigation Links
Accuray Reports Financial Results for First Quarter of Fiscal Year 2014
Date:11/7/2013

3,514Stock-based compensation (c) 

2,1801,7552,097Interest expense, net (d) 

3,3062,0333,331Provision for income taxes 

7875971,706 Adjusted EBITDA 

$   (3,812)$ (11,918)$
(5,862) (a) consists of amortization of intangibles - developed technology, distributor licenses and backlog  (b) consists of depreciation, primarily on property and equipment  (c) consists of stock-based compensation in accordance with ASC 718  (d) consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes 


'/>"/>
SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
2. Accuray Announces First CyberKnife System in South America
3. Accuray Surpasses 600 Installations Globally
4. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
5. Omeros Corporation Reports Third Quarter 2013 Financial Results
6. Global Positron Emission Tomography Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
7. Global In Vitro Fertilization Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
8. Global Biophotonics Market & OSS BSS Industry 2012-2016 Reports
9. China Vanadium Catalyst Market for Sulfuric Acid Production in A New Research Available at MarketReportsChina.com
10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
11. Neurocrine Biosciences Reports Third Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY) today ... Oncology (ASCO) Annual Meeting being held May 29-June 2, ... candidates Stimuvax(R), PX-866 and PX-12 are now available to ... www.abstract.asco.org ., Abstracts include:, ...
... Global biomedical sciences companies,invested more than US$500 million ... on,Singapore,s strong scientific fundamentals, with biomedical sciences R&D,expenditure ... The continued confidence in Singapore points ... to the fast growing Asian,market to fuel their ...
... During Joint Research EMERYVILLE, Calif., May 17 Onyx ... that it has filed a complaint in the United ... asserting its rights to a Phase 2 anti-cancer compound ... In its complaint, Onyx seeks a declaration that fluoro-sorafenib ...
Cached Biology Technology:Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 3Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 2Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 3Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 4Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 5Onyx Pharmaceuticals Files Complaint Against Bayer Corporation 2
(Date:7/31/2015)... , Chine, 31 juillet 2015 ... www.icg-10.org ) sera organisée par le BGI ... Shenzhen en Chine. ... Depuis son inauguration en 2006, l,ICG est devenue ... dans le domaine des « omiques » et c,est aussi ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... it has filed provisional patent 62/198989 for ... invention highlights a method to advance crypto-currencies such as ... introducing a common, uniform way to manage all payments.  ...
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... people don,t think worms are cool. But the tiny flatworm ... very cool indeed: it can regenerate itself from nearly every ... two worms. This amazing ability of the planarian flatworm ... tissue has fascinated scientists since the late 1800s. The worms ...
... with wireless sensor network developers Senceive, to help ... structures in the UK that will save costs ... application area is long-term infrastructure monitoring. The company,s ... assess the condition of railway structures, track, bridges, ...
... in German . Aggressive male mating ... individual but it can drive the species to extinction, an ... the University of Zurich has demonstrated in a mathematical model. ... the behavior of the individual is able to influence processes ...
Cached Biology News:Heads or tails? 2Heads or tails? 3NPL helps Senceive to offer improved monitoring of structural assets across the UK 2Aggressive male mating behavior can endanger species 2
... 5 Fluorescein 6-Fam, Hex, Tet ... Fluorescein Tamra Black Hole Quenchers ... Hex, Tet Tamra, Joe 3 ... Institute, New York Double labelled probes are ...
... The flexible and easy ... used to control all members ... family. It features a clear ... visual assay setup, user-friendly and ...
... Recombinant Enterokinase (rEK) is a highly ... bovine enterokinase, a serine protease which recognizes ... enzyme (AspAspAspAspLys?) and has similar enzymatic activity ... coli and purified to yield the highest ...
Roll of Mesh 5m x 25cm...
Biology Products: